Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study

Background and objectives: It was postulated that in patients with membranous nephropathy (MN), four weekly doses of Rituximab (RTX) would result in more effective B cell depletion, a higher remission rate, and maintaining the same safety profile compared with patients treated with RTX dosed at 1 g...

詳細記述

保存先:
書誌詳細
主要な著者: Fervenza, Fernando C., Abraham, Roshini S., Erickson, Stephen B., Irazabal, Maria Valentina, Eirin, Alfonso, Specks, Ulrich, Nachman, Patrick H., Bergstralh, Eric J., Leung, Nelson, Cosio, Fernando G., Hogan, Marie C., Dillon, John J., Hickson, LaTonya J., Li, Xujian, Cattran, Daniel C.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Nephrology 2010
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2994079/
https://ncbi.nlm.nih.gov/pubmed/20705965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.05080610
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料